Investigational Drug Information for Seviteronel
✉ Email this page to a colleague
What is the development status for investigational drug Seviteronel?
Seviteronel is an investigational drug.
There have been 6 clinical trials for Seviteronel.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2014.
The most common disease conditions in clinical trials are Triple Negative Breast Neoplasms, Prostatic Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Innocrin Pharmaceutical, St Vincent's Hospital, Sydney, and National Cancer Institute (NCI).
Summary for Seviteronel
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 44 |
WIPO Patent Applications | 72 |
Japanese Patent Applications | 5 |
Clinical Trial Progress | Phase 2 (2014-04-01) |
Vendors | 32 |
Recent Clinical Trials for Seviteronel
Title | Sponsor | Phase |
---|---|---|
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer | St Vincent's Hospital, Sydney | Phase 1/Phase 2 |
Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma | St Vincent's Hospital, Sydney | Phase 2 |
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) | Innocrin Pharmaceutical | Phase 1/Phase 2 |
Clinical Trial Summary for Seviteronel
Top disease conditions for Seviteronel
Top clinical trial sponsors for Seviteronel
US Patents for Seviteronel
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |